Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30231169 | 1.00 | NLRP3 (0.51) | NLRP3GAACYP2C19CYP2C9CYP1A2 | |
| SCHEMBL24076255 | 0.94 | NLRP3 (0.51) | NLRP3GAACYP2C19CYP2C9CYP1A2 | |
| SCHEMBL24076307 | 0.93 | NLRP3 (0.58) | NLRP3GAACYP2C19CYP2C9CYP1A2 | |
| SCHEMBL24077343 | 0.92 | CYP2C19 (0.52) | NLRP3GAACYP2C19CYP2C9CYP1A2 | |
| SCHEMBL24076927 | 0.91 | NLRP3 (0.50) | NLRP3GAACYP2C19CYP2C9CYP1A2 | |
| SCHEMBL24076889 | 0.91 | GAA (0.48) | NLRP3GAACYP2C19CYP2C9CYP1A2 | |
| SCHEMBL24077321 | 0.89 | GAA (0.47) | NLRP3GAACYP2C19CYP2C9CYP1A2 | |
| SCHEMBL24077053 | 0.87 | NLRP3 (0.56) | NLRP3KMT2APOLB | |
| SCHEMBL25747492 | 0.85 | NLRP3 (0.51) | NLRP3GAACYP2C19CYP2C9CYP1A2 | |
| SCHEMBL25746184 | 0.85 | GAA (0.53) | NLRP3GAACYP2C19CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | NLRP3 1/4885GAA 4369/4885CYP2C19 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.